Research Studies

Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV

62%

1499. Tesamorelin Reduces Visceral Adipose Tissue and Liver Fat in INSTI-Treated Persons with HIV

63%

Cross-Sectional Study

Abdominal Obesity Indices as Predictors of Psychiatric Morbidity in a Large-Scale Taiwanese Cohort

48%

Computational/Algorithm Study

Design, performance, and charge transfer insights into step-scheme zinc hydroxystannate/titanium dioxide heterostructures for enhanced photocatalytic oxidation of gaseous benzene.

The effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH.

61%

Animal

The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance

13%

The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV

60%

Tesamorelin improves fat quality independent of changes in fat quantity

Determinants of delayed or incomplete diphtheria-tetanus-pertussis vaccination in parallel urban and rural birth cohorts of 30,956 infants in Tanzania

66%

Effects of Tesamorelin, a Growth Hormone–Releasing Factor, in HIV-Infected Patients With Abdominal Fat Accumulation: A Randomized Placebo-Controlled Trial With a Safety Extension

Dedifferentiation maintains melanocyte stem cells in a dynamic niche

16%